Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Strategic Timing of Antiretroviral Treatment (START)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00867048
Recruitment Status : Active, not recruiting
First Posted : March 23, 2009
Last Update Posted : November 12, 2020
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark
Medical Research Council
The Kirby Institute for Infection and Immunity in Society
Washington D.C. Veterans Affairs Medical Center
ANRS, Emerging Infectious Diseases
German Federal Ministry of Education and Research
NEAT - European AIDS Treatment Network
National Health and Medical Research Council, Australia
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Abbott
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Tibotec Pharmaceutical Limited
Information provided by (Responsible Party):
University of Minnesota

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):